Provided By GlobeNewswire
Last update: Jun 25, 2024
The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin, head & neck, and oral cavity.
NASDAQ:DRTS (6/3/2025, 9:57:50 AM)
2.92
-0.01 (-0.34%)
NASDAQ:DRTSW (5/30/2025, 8:00:01 PM)
0.21
-0.04 (-16%)
Find more stocks in the Stock Screener